We developed LATS inhibitors that effectively suppress the expression of ESR1 and revealed a proof of concept that LATS is potential therapeutic target for ER+ breast cancer, particularly those with hormone therapy resistant ESR1 mutations. The gene discussed is ESR1; the disease is breast cancer.